Synonyms: ACY-1215
Compound class:
Synthetic organic
Comment: Rocilinostat is an investigational HDAC6 inhibitor [2]. But note that it exhibits only ~10-fold enzymic selectivity against the class I isoform, HDAC1.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Kalin JH, Bergman JA. (2013)
Development and therapeutic implications of selective histone deacetylase 6 inhibitors. J Med Chem, 56 (16): 6297-313. [PMID:23627282] |
2. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC et al.. (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood, 119 (11): 2579-89. [PMID:22262760] |